AU2012326170B2 - Etanercept formulations stabilized with metal ions - Google Patents

Etanercept formulations stabilized with metal ions Download PDF

Info

Publication number
AU2012326170B2
AU2012326170B2 AU2012326170A AU2012326170A AU2012326170B2 AU 2012326170 B2 AU2012326170 B2 AU 2012326170B2 AU 2012326170 A AU2012326170 A AU 2012326170A AU 2012326170 A AU2012326170 A AU 2012326170A AU 2012326170 B2 AU2012326170 B2 AU 2012326170B2
Authority
AU
Australia
Prior art keywords
etanercept
composition
peak
less
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012326170A
Other languages
English (en)
Other versions
AU2012326170A1 (en
Inventor
Mark Manning
Brian Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AU2012326170A1 publication Critical patent/AU2012326170A1/en
Application granted granted Critical
Publication of AU2012326170B2 publication Critical patent/AU2012326170B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
AU2012326170A 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions Ceased AU2012326170B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US61/548,518 2011-10-18
US201261669480P 2012-07-09 2012-07-09
US61/669,480 2012-07-09
PCT/US2012/060739 WO2013059406A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Publications (2)

Publication Number Publication Date
AU2012326170A1 AU2012326170A1 (en) 2014-04-24
AU2012326170B2 true AU2012326170B2 (en) 2016-12-22

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2012326170A Ceased AU2012326170B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions
AU2012326082A Ceased AU2012326082B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
AU2012326171A Ceased AU2012326171B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
AU2012326084A Ceased AU2012326084B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
AU2012326168A Ceased AU2012326168B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
AU2012326080A Ceased AU2012326080B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2012326082A Ceased AU2012326082B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
AU2012326171A Ceased AU2012326171B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
AU2012326084A Ceased AU2012326084B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
AU2012326168A Ceased AU2012326168B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
AU2012326080A Ceased AU2012326080B2 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine

Country Status (28)

Country Link
US (21) US10293049B2 (cg-RX-API-DMAC7.html)
EP (6) EP2768525B1 (cg-RX-API-DMAC7.html)
JP (6) JP6113176B2 (cg-RX-API-DMAC7.html)
KR (7) KR20140091705A (cg-RX-API-DMAC7.html)
CN (6) CN104010658A (cg-RX-API-DMAC7.html)
AR (6) AR088382A1 (cg-RX-API-DMAC7.html)
AU (6) AU2012326170B2 (cg-RX-API-DMAC7.html)
BR (6) BR112014009022A2 (cg-RX-API-DMAC7.html)
CA (6) CA2851642A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121843T1 (cg-RX-API-DMAC7.html)
DK (1) DK2768525T3 (cg-RX-API-DMAC7.html)
EA (6) EA026410B1 (cg-RX-API-DMAC7.html)
ES (1) ES2734070T3 (cg-RX-API-DMAC7.html)
HK (3) HK1200721A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191215T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045624T2 (cg-RX-API-DMAC7.html)
IL (6) IL231825A0 (cg-RX-API-DMAC7.html)
IN (3) IN2014CN02592A (cg-RX-API-DMAC7.html)
LT (1) LT2768525T (cg-RX-API-DMAC7.html)
MX (7) MX2014004728A (cg-RX-API-DMAC7.html)
PL (1) PL2768525T3 (cg-RX-API-DMAC7.html)
PT (1) PT2768525T (cg-RX-API-DMAC7.html)
RS (1) RS59179B1 (cg-RX-API-DMAC7.html)
SG (6) SG11201401562RA (cg-RX-API-DMAC7.html)
SI (1) SI2768525T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900422T1 (cg-RX-API-DMAC7.html)
TW (6) TWI595883B (cg-RX-API-DMAC7.html)
WO (6) WO2013059412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010658A (zh) * 2011-10-18 2014-08-27 科荣生生物科学公司 使用葡甲胺稳定的依那西普制剂
EP2869817A4 (en) * 2012-07-09 2016-04-06 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
RU2663727C2 (ru) * 2013-05-02 2018-08-08 Мабксьенсе С.А. Альтернативные составы для химерных полипептидов tnfr:fc
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
EP3073992A4 (en) 2013-11-29 2017-09-13 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
EP3236990B1 (en) * 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
WO2016103034A1 (en) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Protein compositions and use thereof
KR102018608B1 (ko) * 2014-12-31 2019-09-06 주식회사 엘지화학 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
CA3040899A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
AU2018374232A1 (en) * 2017-11-30 2020-07-23 Bio-Thera Solutions, Ltd. Liquid preparation of humanized antibody for treating IL-6-related disease
KR20250002808A (ko) * 2017-12-22 2025-01-07 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
WO2022175663A1 (en) 2021-02-17 2022-08-25 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
ATE394123T1 (de) * 2003-02-28 2008-05-15 Ares Trading Sa Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
WO2005082377A1 (ja) * 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
MX2007015476A (es) * 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
PT1962886E (pt) * 2005-12-20 2014-01-07 Bristol Myers Squibb Co Formulações de proteína estáveis
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
MX2008011874A (es) 2006-03-17 2009-01-07 Biogen Idec Inc Composiciones estabilizadas de polipeptidos.
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
WO2008063717A2 (en) * 2006-08-01 2008-05-29 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
CL2007002880A1 (es) * 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
NZ601913A (en) * 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2260054B1 (en) 2008-02-29 2015-06-03 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2563904B1 (en) 2010-04-26 2015-01-21 Novartis AG Improved cell culture medium
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE
LT2726600T (lt) 2011-07-01 2017-05-25 Amgen Inc. Žinduolių ląstelių kultūra
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
EP2729482B1 (en) 2011-07-08 2018-03-07 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
CN104010658A (zh) * 2011-10-18 2014-08-27 科荣生生物科学公司 使用葡甲胺稳定的依那西普制剂
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
US10888619B2 (en) 2021-01-12
TW201325610A (zh) 2013-07-01
EA201490803A1 (ru) 2014-09-30
CA2851642A1 (en) 2013-04-25
US9302002B2 (en) 2016-04-05
AU2012326082A1 (en) 2014-04-24
CA2851639C (en) 2020-12-29
US20130108632A1 (en) 2013-05-02
TW201325609A (zh) 2013-07-01
EP2768525B1 (en) 2019-06-19
EP2768525A1 (en) 2014-08-27
SMT201900422T1 (it) 2019-09-09
IL231828A0 (en) 2014-05-28
US20130101640A1 (en) 2013-04-25
SG11201401567YA (en) 2014-07-30
US20200405865A1 (en) 2020-12-31
BR112014009031A2 (pt) 2017-05-09
US20190314499A1 (en) 2019-10-17
MX367054B (es) 2019-08-02
TWI644681B (zh) 2018-12-21
BR112014009146A2 (pt) 2017-06-13
KR20200008021A (ko) 2020-01-22
EP2768854A4 (en) 2015-03-11
CA2851639A1 (en) 2013-04-25
CY1121843T1 (el) 2020-07-31
JP6104922B2 (ja) 2017-03-29
AU2012326171B2 (en) 2017-03-09
AR088380A1 (es) 2014-05-28
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
BR112014009087A2 (pt) 2017-04-18
AR088460A1 (es) 2014-06-11
JP2014530864A (ja) 2014-11-20
WO2013059406A1 (en) 2013-04-25
US20130108633A1 (en) 2013-05-02
MX2014004725A (es) 2015-02-05
AU2012326170A1 (en) 2014-04-24
US11129876B2 (en) 2021-09-28
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
EP2768532A1 (en) 2014-08-27
HRP20191215T1 (hr) 2019-10-04
JP6199298B2 (ja) 2017-09-20
HK1200718A1 (en) 2015-08-14
US20190290765A1 (en) 2019-09-26
US20190290768A1 (en) 2019-09-26
US20190216930A1 (en) 2019-07-18
AU2012326171A1 (en) 2014-04-24
SG11201401517VA (en) 2014-09-26
MX2014004733A (es) 2015-05-15
MX2014004734A (es) 2015-05-15
US10376588B2 (en) 2019-08-13
JP6110393B2 (ja) 2017-04-05
IL231824A0 (en) 2014-05-28
KR20140091707A (ko) 2014-07-22
EA025663B1 (ru) 2017-01-30
US20190314500A1 (en) 2019-10-17
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (cg-RX-API-DMAC7.html) 2015-06-26
JP2014530863A (ja) 2014-11-20
KR20140097184A (ko) 2014-08-06
EA025267B1 (ru) 2016-12-30
RS59179B1 (sr) 2019-10-31
IL231825A0 (en) 2014-05-28
EP2768531A1 (en) 2014-08-27
EA201490801A1 (ru) 2014-09-30
KR20140091706A (ko) 2014-07-22
EP2768535A1 (en) 2014-08-27
TW201325608A (zh) 2013-07-01
PT2768525T (pt) 2019-07-17
US9943601B2 (en) 2018-04-17
CN104010658A (zh) 2014-08-27
DK2768525T3 (da) 2019-07-22
MX2014004728A (es) 2015-05-15
EA201490817A1 (ru) 2014-09-30
MX2014004732A (es) 2015-05-15
JP6220788B2 (ja) 2017-10-25
AU2012326080B2 (en) 2017-02-16
MX2014004726A (es) 2015-05-15
KR102068462B1 (ko) 2020-01-22
SI2768525T1 (sl) 2019-10-30
US11135267B2 (en) 2021-10-05
CA2851635A1 (en) 2013-04-25
US10772963B2 (en) 2020-09-15
TW201325607A (zh) 2013-07-01
ES2734070T3 (es) 2019-12-04
TWI595883B (zh) 2017-08-21
CN104010657A (zh) 2014-08-27
US9801942B2 (en) 2017-10-31
US9770510B2 (en) 2017-09-26
AU2012326082B2 (en) 2016-12-15
HK1200722A1 (en) 2015-08-14
US10213508B2 (en) 2019-02-26
AR088382A1 (es) 2014-05-28
LT2768525T (lt) 2019-09-25
IL231827A0 (en) 2014-05-28
CN104010654B (zh) 2017-10-27
BR112014009022A2 (pt) 2017-05-02
WO2013059408A1 (en) 2013-04-25
BR112014009131A8 (pt) 2017-06-20
KR102163150B1 (ko) 2020-10-08
EP2768525A4 (en) 2015-07-15
CN104011073B (zh) 2017-08-25
US10980885B2 (en) 2021-04-20
SG11201401576WA (en) 2014-10-30
US20130101584A1 (en) 2013-04-25
TW201325606A (zh) 2013-07-01
HK1200721A1 (en) 2015-08-14
US20190298837A1 (en) 2019-10-03
EP2768531A4 (en) 2015-03-11
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
CA2851646A1 (en) 2013-04-25
AR088381A1 (es) 2014-05-28
CN104010654A (zh) 2014-08-27
AU2012326084B2 (en) 2016-12-15
IN2014CN02592A (cg-RX-API-DMAC7.html) 2015-09-04
EP2768533A4 (en) 2015-03-11
US20160317667A1 (en) 2016-11-03
AU2012326084A1 (en) 2014-04-17
SG11201401519RA (en) 2014-07-30
JP2014530255A (ja) 2014-11-17
IL231829A0 (en) 2014-05-28
US20160199489A1 (en) 2016-07-14
SG11201401563SA (en) 2014-09-26
IL231826A0 (en) 2014-05-28
HK1200720A1 (en) 2015-08-14
AR088379A1 (es) 2014-05-28
KR20140083037A (ko) 2014-07-03
TWI619504B (zh) 2018-04-01
JP2014530256A (ja) 2014-11-17
MX2019009176A (es) 2019-10-07
JP6220789B2 (ja) 2017-10-25
KR20140079491A (ko) 2014-06-26
US10987405B2 (en) 2021-04-27
WO2013059407A1 (en) 2013-04-25
US20190184017A1 (en) 2019-06-20
US20180125982A1 (en) 2018-05-10
EA201490802A1 (ru) 2014-08-29
EP2768533A1 (en) 2014-08-27
CA2851628A1 (en) 2013-04-25
HK1200851A1 (en) 2015-08-14
BR112014009073A2 (pt) 2017-05-09
JP2014530862A (ja) 2014-11-20
US10980884B2 (en) 2021-04-20
BR112014009146A8 (pt) 2017-06-20
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
EA201490804A1 (ru) 2014-09-30
BR112014009131A2 (pt) 2017-06-13
US20190314498A1 (en) 2019-10-17
AU2012326168B2 (en) 2016-12-15
AR088383A1 (es) 2014-05-28
AU2012326168A1 (en) 2014-04-24
EA026410B1 (ru) 2017-04-28
CN103998060B (zh) 2016-12-21
EA201490815A1 (ru) 2014-09-30
CN103998060A (zh) 2014-08-20
KR20140091705A (ko) 2014-07-22
US20180193463A1 (en) 2018-07-12
EP2768854A1 (en) 2014-08-27
US20190290767A1 (en) 2019-09-26
EA027325B1 (ru) 2017-07-31
EP2768535A4 (en) 2015-03-11
IN2014CN02527A (cg-RX-API-DMAC7.html) 2015-06-26
US20190290766A1 (en) 2019-09-26
HUE045624T2 (hu) 2020-01-28
JP6113176B2 (ja) 2017-04-12
CA2851651A1 (en) 2013-04-25
PL2768525T3 (pl) 2019-10-31
SG11201401562RA (en) 2014-09-26
TW201325611A (zh) 2013-07-01
CN103998061A (zh) 2014-08-20
AU2012326080A1 (en) 2014-04-24
JP2014530254A (ja) 2014-11-17
WO2013059412A1 (en) 2013-04-25
EP2768532A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
US11129876B2 (en) Etanercept formulations stabilized with amino acids
EP2869816A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
US10493151B2 (en) Etanercept formulations stabilized with sodium chloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired